Frontiers in endocrinology · 2026
Premature ovarian insufficiency in patients with systemic lupus erythematosus on cyclophosphamide: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
García-Sáenz Manuel Ramón, Ramírez-Rentería Claudia, Espinosa-Cárdenas Etual, Sosa-Eroza Ernesto, Doval-Caballero José Luis Eduardo, Gete Palacios Paulo César, Pazos-Pérez Fabiola, Ocampo-Torres Mario César, Catana-Hernández Rocío, Vázquez-Zaragoza Miguel Ángel, Camargo-Coronel Adolfo, Gómez-Bernal Juan Rodrigo, Ferreira-Hermosillo Aldo
Аннотация
BACKGROUND: Premature ovarian insufficiency (POI) is a major long-term adverse effect of cyclophosphamide (CYC) therapy in systemic lupus erythematosus (SLE). Reported prevalence varies due to differences in populations, protocols, and diagnostic criteria. Objective: To estimate the prevalence of POI in women with SLE exposed to CYC and explore sources of heterogeneity.
METHODS: MEDLINE, Embase, Web of Science, Scopus, and LILACS were searched from inception through October 2024. Twenty-one studies were included in the systematic review; 12 CYC-exposed cohorts contributed to the primary meta-analysis. Two reviewers independently extracted data and assessed study quality using the Joanna Briggs Institute checklist.
RESULTS: The pooled prevalence of POI in SLE treated with CYC was 15% (95% CI 7-26%), with substantial heterogeneity (I2 = 85%; Cochran's Q = 73.98 p <0.0001; tau2 = 0.0353). In contrast, prevalence among unselected SLE populations was markedly lower, confirming the potential gonadotoxic effect of CYC. Temporal analysis showed reduced prevalence in studies published after 2005 (9%) compared with pre-2005 (29%), coinciding with adoption of Euro-Lupus low-dose protocols. Meta-regression identified age at exposure as a significant predictor (β = 0.21, 95% CI: 0.04-0.38, p = 0.017). Cumulative CYC dose was not independently associated with prevalence, likely reflecting the widespread adoption of lower-dose regimens after 2005. Methodological sensitivity analyses using logit transformation (20.0%, 95% CI 12.7-30.1) and GLMM (14.5%, 95% CI 7.1-27.2) were added to assess model robustness. Funnel-plot and the Egger's test indicated no evidence of publication bias (p = 0.91).
CONCLUSIONS: Women with SLE treated with CYC show a substantial burden of POI, with an estimated prevalence of approximately 15%. These results underscore the need for standardized diagnostic criteria, fertility counseling, and individualized treatment decisions.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD42025641213.
METHODS: MEDLINE, Embase, Web of Science, Scopus, and LILACS were searched from inception through October 2024. Twenty-one studies were included in the systematic review; 12 CYC-exposed cohorts contributed to the primary meta-analysis. Two reviewers independently extracted data and assessed study quality using the Joanna Briggs Institute checklist.
RESULTS: The pooled prevalence of POI in SLE treated with CYC was 15% (95% CI 7-26%), with substantial heterogeneity (I2 = 85%; Cochran's Q = 73.98 p <0.0001; tau2 = 0.0353). In contrast, prevalence among unselected SLE populations was markedly lower, confirming the potential gonadotoxic effect of CYC. Temporal analysis showed reduced prevalence in studies published after 2005 (9%) compared with pre-2005 (29%), coinciding with adoption of Euro-Lupus low-dose protocols. Meta-regression identified age at exposure as a significant predictor (β = 0.21, 95% CI: 0.04-0.38, p = 0.017). Cumulative CYC dose was not independently associated with prevalence, likely reflecting the widespread adoption of lower-dose regimens after 2005. Methodological sensitivity analyses using logit transformation (20.0%, 95% CI 12.7-30.1) and GLMM (14.5%, 95% CI 7.1-27.2) were added to assess model robustness. Funnel-plot and the Egger's test indicated no evidence of publication bias (p = 0.91).
CONCLUSIONS: Women with SLE treated with CYC show a substantial burden of POI, with an estimated prevalence of approximately 15%. These results underscore the need for standardized diagnostic criteria, fertility counseling, and individualized treatment decisions.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD42025641213.